Abstract
Avastin generates a decrease in vascular permeability in GBM which is marked by a decrease in cerebral edema and a decrease in contrast enhancement as seen on magnetic resonance imaging. These effects on the tumor vasculature may be mistakenly referred to as tumor responses because the historical method of measuring tumor response is based on tumor size assessed by contrast enhancement. This may explain why the few prospective phase II trials and several retrospective studies of Avastin in GBM report high radiographic response rates (30-60%) but modest improvements in progression-free survival and overall survival. Improved radiographic criteria for detecting disease progression in this context are needed and should be used in larger, randomized clinical trials which determine the magnitude of the survival benefit from Avastin.
Related Journals
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Diabetes Reviews
Current Neurovascular Research
Current Respiratory Medicine Reviews
Current Pediatric Reviews
Infectious Disorders - Drug Targets
Current Stem Cell Research & Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets
Current Alzheimer Research
Current Aging Science
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents